Neil F. McFarlane
CIK 1681098 · President and CEO · last filed 2026-10-13
Neil F. McFarlane is a President and CEO who has filed 33 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for ZVRA, was dated Oct 13, 2026. Across all open-market trades the lifetime net is −$2.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZVRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
12255 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | President and CEO | 437,225 | $10.33 | $4.52M | -$2.14M | 9 | 2026-10-13 |
| COLL | Director | 49,365 | $23.75 | $1.17M | $0 | 4 | 2024-05-16 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Executive Officer | 0 | $8.22 | $0 | $0 | 4 | 2021-11-24 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Operating Officer | 27,972 | — | — | -$552.6K | 10 | 2019-05-16 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-13 | ZVRA | Notice (144) | −20,000 | -$227.8K | EDGAR |
| 2026-10-13 | ZVRA | Mixed | +30,000 | -$224.9K | EDGAR |
| 2026-02-10 | ZVRA | Mixed | +22,875 | -$125.2K | EDGAR |
| 2026-02-02 | ZVRA | Notice (144) | −105,625 | -$950.6K | EDGAR |
| 2026-02-02 | ZVRA | Mixed | +142,334 | -$853.4K | EDGAR |
| 2025-10-10 | ZVRA | Notice (144) | −19,500 | -$211.0K | EDGAR |
| 2025-10-10 | ZVRA | Mixed | +30,500 | -$210.9K | EDGAR |
| 2025-02-14 | ZVRA | Sell (S) | −91,817 | -$727.4K | EDGAR |
| 2025-02-13 | ZVRA | Notice (144) | −91,817 | -$708.8K | EDGAR |
| 2025-02-10 | ZVRA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.